Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country

Table 1 Sustained virologic response according to patient characteristics at baseline (n = 288) n (%)

	Achieved SVR		P value
	Yes (n = 237)	No (n = 51)
Demographics
Sex
Male	101 (87.1)	15 (12.9)	0.081
Female	136 (79.1)	36 (20.9)
Age
Mean ± SD	45.9 ± 10.4	50.1 ± 8.5	0.007
Median (range)	48.00 (11.0-68.0)	49.00 (34.0-66.0)	0.016
≤ 20	5 (100)	0 (0)	0.017
21-40	57 (87.7)	8 (12.3)
41-60	164 (82.4)	35 (17.6)
> 60	11 (57.9)	8 (42.1)
Pretreatment conditions/comorbidities
HCV/HIV coinfection	4 (100)	0 (0)	0.350
Diabetes mellitus	21 (91.3)	2 (8.7)	0.238
Previous alcohol consumption	45 (81.8)	10 (18.2)	0.919
High pretreatment ALT (> 40)	166 (81.8)	37 (18.2)	0.722
High pretreatment Hgb (≥ 12 g/dL)	182 (81.3)	42 (18.8)	0.386
High pretreatment WBC (≥ 4000 mm3)	225 (82.7)	47 (17.3)	0.432
High pretreatment platelet (≥ 150000/mm3)	189 (84.8)	34 (15.2)	0.043
High pretreatment albumin (≥ 3.5 g/dL)	212 (84.5)	39 (15.5)	0.012
High pretreatment HCV RNA (≥ 800000 IU/mL)	144 (79.1)	38 (20.9)	0.065
Liver stiffness
F ≤ 2	133 (92.4)	11 (7.6)	< 0.001
F3-4	104 (72.2)	40 (27.8)
IL-28B polymorphism
rs8099917TT	204 (82.3)	44 (17.7)	0.634
rs8099917Non-TT	18 (78.3)	5 (21.7)
Unknown	15 (88.2)	2 (11.8)
rs12979860CC	196 (82.4)	42 (17.6)	0.618

ALT: Alanine aminotransferase; HCV: Hepatitis C virus; Hgb: Hemoglobin; HIV: Human immunodeficiency virus; SVR: Sustained virologic response; WBC: White blood cell.